Home>Topics>Stocks>Arena Pharmaceuticals

Arena Pharmaceuticals ARNA

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Advertising And The Belviq Re-Launch

      Headlines

      Mon, 25 Aug 2014

      By Spencer Osborne : July of 2014 marked the "re-launch" of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) and marketing partner Eisai (OTCPK: ESALY ). Belviq had its initial launch in June of 2013 and sales

    2. Belviq Sales Rise 2%

      Headlines

      Mon, 25 Aug 2014

      By Spencer Osborne : Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) continued to buck the seasonality factor by bringing in a 2% increase in week over week sales according to industry tracker

    3. MannKind Corp. And The Folly Of Cult Biotech Stocks

      Headlines

      Mon, 18 Aug 2014

      By EnhydrisPECorp : I think of myself as a contrarian investor with a long-term outlook. And for the most part, this approach has served me well over the years. For example, I used some of my earnings from my first job following high school graduation to buy shares of Johnson & Johnson (NYSE: JNJ

    4. Arena And VIVUS: A Case Study In Small-Cap Pharma

      Headlines

      Mon, 18 Aug 2014

      By Jason Ditz : For investors who play the small cap pharmaceutical game, Arena Pharmaceuticals (NASDAQ: ARNA ) and VIVUS Inc (NASDAQ: VVUS ) need no introduction. 2012 was the year of the weight loss drug, and consequently the year

    5. Belviq Sales Flatten Out But Edge Above Qsymia

      Headlines

      Fri, 15 Aug 2014

      By Spencer Osborne : The bad news for Arena Pharmaceuticals (NASDAQ: ARNA ) investors this week is that scripts were slightly down. The good news this week is that for the first time (using IMS Health

    6. FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another

      Headlines

      Fri, 15 Aug 2014

      a ratio of reported adverse events to the number of scripts sold. I analyzed the data for Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ). There are a couple of items that investors should consider

    7. For Lexicon Pharmaceuticals, No News Remains Bad News

      Headlines

      Mon, 11 Aug 2014

      Eisai's acquisition of MGI Pharma and the somewhat unconventional licensing/marketing agreement with Arena Pharmaceuticals (NASDAQ: ARNA ) for its obesity drug Belviq. Although Lexicon shareholders may regard Complete Story »

    8. Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain

      Headlines

      Fri, 8 Aug 2014

      By Spencer Osborne : Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) continue to buck the seasonality of the weight loss sector with a 3.6% week over week gain. While 3.6% may not seem impressive

    9. Vivus Beats The Street - Still Has A Loss

      Headlines

      Fri, 8 Aug 2014

      By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced its quarterly earnings today and beat the street by $0.4 per share. The news sent the stock up in after hours trading, and while beating the street is always good, the company did still post a loss of $0.25 per share. Getting down to the ...

    10. Orexigen Hits Expectations But That Is Not The Big News

      Headlines

      Thu, 7 Aug 2014

      By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced its Q2 financial results this morning and the loss of $0.21 cents came in line with expectations. The equity moved up early in the session because of positive outlooks for the anti-obesity drug NB32, also known as Contrave. Orexigen is ...

    « Prev12345Next »
    Content Partners